06/01/2026
This is a milestone worth sharing.
NOUS-209, an investigational therapy designed to intercept cancer before it develops in Lynch syndrome carriers, has been granted FDA Fast Track Designation. The Phase 1b/2 results, the first clinical evidence of cancer interception in Lynch syndrome, were recently published in Nature Medicine.
For our community, this matters. Lynch syndrome carries up to an 80% lifetime cancer risk, and for most carriers, surveillance is still the primary management tool. Research in immunoprevention, stopping cancer from developing in the first place, is working toward a different future.
This program is still advancing toward a registration trial, but Fast Track status accelerates the FDA dialogue. Progress is being made.
AliveandKick'n will keep following this research and amplifying what it means for our community. https://lnkd.in/eFhP5jFg